{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:46:27Z","timestamp":1791891987857,"version":"4.3.4"},"reference-count":14,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Many people with chronic hepatitis C infection don't engage in treatment. To eliminate hepatitis C and avoid health inequalities therapy must be provided to everyone. In other diseases peers with lived experience of the condition have improved care but, for hepatitis C, studies have not shown unequivocal benefit. We completed a retrospective analysis of the English National Health Service treatment registry comparing treatment networks with and without peers using Bayesian Poisson (for count outcomes) or Bayesian Binomial (for proportion outcomes) mixed effects models with time fixed effects. For each outcome, we estimated relative ratio (RR\u2010Poisson model) or odds ratio (Odds Ratio (OR)\u2010Binomial model) between peer and non\u2010peer networks. We analysed 30,729 patients within 20 operational delivery networks. In networks with peers there was an increase in the number of people initiating therapy (RR 1.12 95%, credible interval 1.02\u20131.21) and an increase in the proportion completing therapy (OR 2.45 95%, credible interval 1.49\u20133.84). However, we saw no change in proportions of people using drugs who initiated therapy nor any significant change in virological response (OR 1.14 95% credible interval 0.979\u20131.36). We repeated the analysis looking at the impact of peers two months after they had been introduced, when they had established networks of contacts, and saw an increase in the proportion of people treated in addiction services. In treating patients with chronic hepatitis C infection the inclusion of peer supporters may increase the number of people who initiate and complete antiviral therapy.<\/jats:p>","DOI":"10.1111\/jvh.13626","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T20:24:48Z","timestamp":1634761488000},"page":"43-51","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Role of peer support in a hepatitis C elimination programme"],"prefix":"10.1111","volume":"29","author":[{"given":"Davina Varsha","family":"Jugnarain","sequence":"first","affiliation":[{"name":"Barts Health Liver Centre The Blizard Institute Queen Mary University of London The Hepatitis C Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Halford","sequence":"additional","affiliation":[{"name":"Barts Health Liver Centre The Blizard Institute Queen Mary University of London The Hepatitis C Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Smith","sequence":"additional","affiliation":[{"name":"Barts Health Liver Centre The Blizard Institute Queen Mary University of London The Hepatitis C Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hickman","sequence":"additional","affiliation":[{"name":"Population Health Sciences Bristol Medical School Bristol University Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantelis","family":"Samartsidis","sequence":"additional","affiliation":[{"name":"MRC Biostatistics Unit University of Cambridge Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham R.","family":"Foster","sequence":"additional","affiliation":[{"name":"Barts Health Liver Centre The Blizard Institute Queen Mary University of London The Hepatitis C Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"Hepatitis C in the UK 2019.2019(Accessed 17\/6\/2019 athttps:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/831155\/Hepatitis_C_in_the_UK_2019_report.pdf)."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1496"},{"key":"e_1_2_8_4_1","first-page":"809","article-title":"Clinical effectiveness of pharmacist\u2010led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster\u2010randomised trial. Lancet","volume":"5","author":"Radley A","year":"2020","journal-title":"Gastroenterol Hepatol"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13233"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2018.11.004"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-019-1300-2"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14569"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz166"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216123"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz452"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2017.05.031"},{"key":"e_1_2_8_13_1","unstructured":"Clinical Commissioning Policy Statement: Treatment of chronic Hepatitis C in patients with cirrhosis2015athttps:\/\/www.england.nhs.uk\/commissioning\/wp\u2010content\/uploads\/sites\/12\/2015\/06\/hep\u2010c\u2010cirrhosis\u2010polcy\u2010statmnt\u20100615.pdf"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15780"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8451"}],"updated-by":[{"DOI":"10.1111\/jvh.13794","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000}}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13626","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.13626","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T10:50:15Z","timestamp":1692960615000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1111\/jvh.13626"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13626","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"assertion":[{"value":"2021-08-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}